
Commentary|Videos|November 3, 2023
Caring for a Wig in Patients With Cancer-Related Hair Loss
Author(s)Kristie L. Kahl
In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss how patients with cancer can care for their wig.
Advertisement
In part four of CURE’s “Confidently You: Choosing and Styling Wigs that Look and Feel Right” webinar, Daniela Hernandez-Salas, a Look Good Feel Better volunteer, discussed how to wash and care for a wig worn by patients with cancer experiencing treatment-related hair loss.
Summary:
00:04 – Shampooing a wig
- If a patient wears one wig every day, they should shampoo it every two to three weeks; however, this could be dependent on perspiration and wear.
- For example, Daniela Hernandez-Salas noted that during the summer or in warmer weather, patients may want to shampoo more often.
- She also mentioned that the less a wig is shampooed, the longer it will last.
00:44 – Shampooing a synthetic wig.
- The speaker suggested using lukewarm water with wig-specific shampoo in a basin of water.
- She motioned to turn the wig inside out and dip it up and down in the basin, working the shampoo into the fibers, followed by rinsing it under water.
- Last, she recommended squeezing the water out of the wig, not to twist or wring the synthetic hair, and let it air dry for seven to eight hours.
02:53 – Tips and tricks for washing wigs.
- Hernandez-Salas recommended against using blow dryers, curling irons or any kind of instrument that is going to cinch the fiber again to prevent damage.
- She also offered an example of being careful when cooking in either the stove or oven.
- Further, using a sweat liner or wig cap can help to catch sweat and protect ones skin in hot weather.
- When not wearing their wig, patients should keep them on a tall stand or to lay them flat on tissue paper.
- Lastly, Hernandez-Salas reminded the audience to keep wigs away from heat sources, including cars.
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article

The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.

A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.

The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.

The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Advertisement
Advertisement
Trending on CURE
1
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
2
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
3
Anktiva for Papillary Bladder Cancer: What Patients Should Know
4
Why Biomarker Testing Can Change a Brain Tumor Diagnosis
5





